JP2019501140A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501140A5
JP2019501140A5 JP2018527799A JP2018527799A JP2019501140A5 JP 2019501140 A5 JP2019501140 A5 JP 2019501140A5 JP 2018527799 A JP2018527799 A JP 2018527799A JP 2018527799 A JP2018527799 A JP 2018527799A JP 2019501140 A5 JP2019501140 A5 JP 2019501140A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527799A
Other languages
English (en)
Japanese (ja)
Other versions
JP6882289B2 (ja
JP2019501140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063485 external-priority patent/WO2017091661A1/en
Publication of JP2019501140A publication Critical patent/JP2019501140A/ja
Publication of JP2019501140A5 publication Critical patent/JP2019501140A5/ja
Priority to JP2021078741A priority Critical patent/JP7112567B2/ja
Application granted granted Critical
Publication of JP6882289B2 publication Critical patent/JP6882289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527799A 2015-11-25 2016-11-23 二環式ｂｅｔブロモドメイン阻害剤及びその使用 Active JP6882289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078741A JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259894P 2015-11-25 2015-11-25
US62/259,894 2015-11-25
PCT/US2016/063485 WO2017091661A1 (en) 2015-11-25 2016-11-23 Bicyclic bet bromodomain inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078741A Division JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Publications (3)

Publication Number Publication Date
JP2019501140A JP2019501140A (ja) 2019-01-17
JP2019501140A5 true JP2019501140A5 (https=) 2020-01-09
JP6882289B2 JP6882289B2 (ja) 2021-06-02

Family

ID=57543210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018527799A Active JP6882289B2 (ja) 2015-11-25 2016-11-23 二環式ｂｅｔブロモドメイン阻害剤及びその使用
JP2021078741A Active JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078741A Active JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Country Status (8)

Country Link
US (2) US10508106B2 (https=)
EP (2) EP4050005B1 (https=)
JP (2) JP6882289B2 (https=)
CN (2) CN115806550B (https=)
AU (3) AU2016361441B2 (https=)
CA (1) CA3006300C (https=)
ES (2) ES2918589T3 (https=)
WO (1) WO2017091661A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
CN109111426B (zh) * 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
WO2019201296A1 (zh) * 2018-04-18 2019-10-24 南京明德新药研发有限公司 作为rho激酶抑制剂的吡唑类化合物
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020219168A1 (en) 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof
CA3139018A1 (en) * 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
US20240190828A1 (en) * 2021-02-11 2024-06-13 The Medical College Of Wisconsin, Inc. Small Molecule Inhibitors of PBRM1-BD2
KR20230159543A (ko) * 2021-03-26 2023-11-21 메드샤인 디스커버리 아이엔씨. 6-카바메이트로 치환된 헤테로방향족 고리 유도체
JPWO2024043319A1 (https=) * 2022-08-26 2024-02-29
WO2024235225A1 (zh) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2025209570A1 (zh) * 2024-04-03 2025-10-09 北京大学 Bet抑制剂及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
US6262069B1 (en) * 1997-08-29 2001-07-17 Protherics Molecular Design Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
SE0102858D0 (sv) 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP2650286A1 (en) 2004-02-19 2013-10-16 Rexahn Pharmaceuticals, Inc. Quinazoline derivatives and therapeutic use thereof
DK1854789T3 (da) * 2005-02-23 2013-10-21 Shionogi & Co Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2006121767A2 (en) * 2005-05-06 2006-11-16 Apath, Llc 4-aminoquinoline compounds for treating virus-related conditions
WO2008054599A2 (en) * 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
GB0705915D0 (en) * 2007-03-28 2007-05-09 Helperby Therapeutics Ltd New use
EP2152672A1 (en) * 2007-05-24 2010-02-17 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
JP5301456B2 (ja) 2007-11-12 2013-09-25 Ｍｓｄ株式会社 ヘテロアリールオキシキナゾリン誘導体
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2566477B1 (en) * 2010-05-07 2015-09-02 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
WO2011156626A1 (en) * 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2011289230B2 (en) * 2010-08-13 2014-09-04 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
EP2685980B1 (en) * 2011-03-17 2017-12-06 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
CA2840627A1 (en) * 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
US9012443B2 (en) * 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US20130225611A1 (en) * 2011-12-09 2013-08-29 The Regents Of The University Of California Compositions and Methods for Reducing Cancer Cell Proliferation and Modulating Importin-Beta Function
US20130281397A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9201821B2 (en) * 2012-09-27 2015-12-01 Apple Inc. Interrupt timestamping
WO2014055955A1 (en) * 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
US9977024B2 (en) * 2012-12-09 2018-05-22 The Scripps Research Institute Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines
CA2895129C (en) * 2012-12-20 2022-07-05 Sanford-Burnham Medical Research Institute Quinazoline neurotensin receptor 1 agonists and uses thereof
EA201591746A1 (ru) * 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
JP6461118B2 (ja) * 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP6542212B2 (ja) * 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
CN106536507B (zh) * 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
US11034757B2 (en) * 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
JP6599908B2 (ja) * 2014-06-25 2019-10-30 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体１の小分子アゴニスト
WO2016022460A1 (en) * 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
WO2016120808A1 (en) 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
EP3072891A1 (en) * 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途

Similar Documents

Publication Publication Date Title
JP2019501140A5 (https=)
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
WO2008151304A8 (en) Selective inhibitors for cyclin-dependent kinases
MX2023002688A (es) Compuestos farmaceuticos de arilo, heteroarilo, y heterociclicos para el tratamiento de trastornos medicos.
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
WO2020212895A1 (en) Method and apparatus to facilitate the binding of the gap protein to the mutant ras protein by molecular agents to cure ras-mutation related cancers
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
JOP20200114A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
CN111902417A (zh) 一种二芳基巨环化合物、药物组合物以及其用途
JP2008523018A5 (https=)
WO2018023072A3 (en) Compounds and compositions and uses thereof
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
JP2019510075A5 (https=)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
DE602006019296D1 (de) Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
NO20090073L (no) 1,3-disubstitue 4-metyl-1H-pyrol-2-karboksamider og deres anvendelse for fremstlling av medikamenter
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
DE602007004881D1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
CN109983015A (zh) 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用